Treatment of Untreated Acute Myeloid Leukemia

Standard treatment of untreated acute myeloid leukemia (AML) during the remission induction phase depends on the subtype of AML and may include:

• combination chemotherapy that includes
• combination chemotherapy with targeted therapy ( or ), for people whose AML has a mutation in the FLT3 gene
• combination chemotherapy with the targeted therapy drug
• intrathecal chemotherapy (cytarabine or ), for central nervous system (CNS) leukemia
• supportive care

For older adults or people who are unable or unwilling to receive intensive chemotherapy, the following may be continued as long as the person benefits or until toxic effects occur:

• targeted therapy (, , , , or
• low-dose chemotherapy (, low-dose , or )
• targeted therapy with low-dose chemotherapy
• intrathecal chemotherapy, for CNS leukemia
• supportive care

To learn more about these treatments, see the Treatment Option Overview.

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.